MA54525A - Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie - Google Patents

Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie

Info

Publication number
MA54525A
MA54525A MA054525A MA54525A MA54525A MA 54525 A MA54525 A MA 54525A MA 054525 A MA054525 A MA 054525A MA 54525 A MA54525 A MA 54525A MA 54525 A MA54525 A MA 54525A
Authority
MA
Morocco
Prior art keywords
disease
treating
methods
bispecific antibodies
bispecific
Prior art date
Application number
MA054525A
Other languages
English (en)
Inventor
Alexander Berthold Hendrik Bakker
Cornelis Jacob Johannes George Bol
Leonardo Andres Sirulnik
Loo Pieter Fokko Van
Ernesto Isaac Wasserman
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MA54525A publication Critical patent/MA54525A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA054525A 2018-12-20 2019-12-20 Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie MA54525A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18214478 2018-12-20

Publications (1)

Publication Number Publication Date
MA54525A true MA54525A (fr) 2021-10-27

Family

ID=65013454

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054525A MA54525A (fr) 2018-12-20 2019-12-20 Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie

Country Status (7)

Country Link
US (2) US11873338B2 (fr)
EP (1) EP3898685A1 (fr)
JP (2) JP2022521036A (fr)
CN (2) CN114344461A (fr)
MA (1) MA54525A (fr)
TW (1) TWI908715B (fr)
WO (1) WO2020130829A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160054466A (ko) * 2013-09-10 2016-05-16 히타치가세이가부시끼가이샤 슬러리, 연마액 세트, 연마액, 기체의 연마 방법 및 기체
US11873338B2 (en) 2018-12-20 2024-01-16 Merus N.V. CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease
US20250084158A1 (en) * 2021-07-20 2025-03-13 Abl Bio Inc. Anti-cll-1 antibodies and uses thereof
CN118922208A (zh) * 2022-02-28 2024-11-08 贾斯帕医疗公司 用于消耗患病造血干细胞的组合物和方法
CA3261708A1 (fr) * 2022-08-09 2024-02-15 Qlsf Biotherapeutics, Inc. Anticorps se liant à clec12a

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322547A1 (fr) 2003-06-25 2011-05-18 Crucell Holland B.V. Lectin specifique de cellules myeloides
CA2569509C (fr) 2004-06-03 2014-08-12 Novimmune S.A. Anticorps anti-cd3 et leurs methodes d'utilisation
WO2008027236A2 (fr) 2006-08-30 2008-03-06 Genentech, Inc. Anticorps multispécifiques
EP2147594B1 (fr) 2008-06-27 2013-11-13 Merus B.V. Mammifères non humains produisant un anticorps
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
US8507222B2 (en) 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
WO2015015373A1 (fr) 2013-08-02 2015-02-05 BSH Bosch und Siemens Hausgeräte GmbH Système de table de cuisson
US10501545B2 (en) * 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
US9914777B2 (en) * 2015-07-10 2018-03-13 Merus N.V. Human CD3 binding antibody
WO2017167350A1 (fr) * 2016-03-30 2017-10-05 Horst Lindhofer Anticorps multispécifiques destinés à être utilisés pour le traitement d'un néoplasme du tractus urinaire
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
JP7784795B2 (ja) 2016-11-15 2025-12-12 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
US11873338B2 (en) * 2018-12-20 2024-01-16 Merus N.V. CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease

Also Published As

Publication number Publication date
TW202034952A (zh) 2020-10-01
JP2022521036A (ja) 2022-04-05
CN113366018A (zh) 2021-09-07
US20220010013A1 (en) 2022-01-13
CN114344461A (zh) 2022-04-15
US20240262912A1 (en) 2024-08-08
JP2024144441A (ja) 2024-10-11
WO2020130829A1 (fr) 2020-06-25
EP3898685A1 (fr) 2021-10-27
TWI908715B (zh) 2025-12-21
US12503509B2 (en) 2025-12-23
US11873338B2 (en) 2024-01-16

Similar Documents

Publication Publication Date Title
MA54525A (fr) Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie
MA51631A (fr) Anticorps anti-pd1 et méthodes de traitement
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
EP3762015A4 (fr) Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
EP3920923A4 (fr) Agents thérapeutiques et méthodes de traitement
MA71708A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
EP3402533A4 (fr) Méthodes et compositions pour le traitement d'une maladie neurologique
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3846830A4 (fr) Méthodes et compositions pour le traitement de maladie musculo-squelettiques
EP3762505A4 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
MA45997A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d
EP3790540A4 (fr) Méthodes de traitement et de limitation du developpement de troubles neurologiques liés à une maladie cardiovasculaire
MA54313A (fr) Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
MA46842A (fr) Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
FR25C1007I1 (fr) Formulations d'épinéphrine intranasale et méthodes de traitement d'une maladie
MA55375A (fr) Méthodes thérapeutiques de traitement de l'hépatite b
EP3716875A4 (fr) Appareil et procédé pour le traitement d'une maladie prostatique
EP3716949A4 (fr) Méthodes de traitement d'une maladie auto-immune
EP3920940A4 (fr) Méthodes de prévention et de traitement d'une inflammation et d'une maladie inflammatoire
EP3976053A4 (fr) Compositions et méthodes de traitement d'une maladie métabolique
MA48751A (fr) Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax
MA54827A (fr) Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl